Skip to content

Manfred Spitzer

6 papers in the library · 275 citations · publishing 1998-2006

Papers

Sort Most recent Most cited

Electroconvulsive therapy in the treatment of depression in a former ecstasy user

Journal of Psychopharmacology November 1, 2006 Roland W. Freudenmann, Carlos Schönfeldt-lecuona, Manfred Spitzer et al. 4 citations

Depression in former ecstasy users may not respond to selective serotonin reuptake inhibitors (SSRIs) possibly due to damaged serotonergic synapses following long-term heavy ecstasy use. We report findings in a patient suffering from MDMA-induced depression which was refractory to several antidepressive medications including selective noradrenergic reuptake inhibitor (SNRI) and SSRI. An add-on...

The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA)

CNS Drug Reviews June 1, 2004 Roland W. Freudenmann, Manfred Spitzer 41 citations

ABSTRACT This paper reviews the pharmacology and toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA, “eve”). MDEA is a ring‐substituted amphetamine (RSA) like MDMA, its well known N‐methyl analog. Both have become very popular substances of abuse in the techno‐ and house‐music scene. They can evoke psychomotor stimulation, mild alterations of perception, sensations of closeness and a...

Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences August 15, 2003 Jochen Buechler, Matthias Schwab, Gerd Mikus et al.

An enantioselective HPLC method has been developed and validated for the stereospecific analysis of N-ethyl-3,4-methylenedioxyamphetamine (MDE) and its major metabolites N-ethyl-4-hydroxy-3-methoxyamphetamine (HME) and 3,4-methylenedioxyamphetamine (MDA). These compounds have been analyzed both from human plasma and urine after administration of 70 mg pure MDE-hydrochloride enantiomers to four...

Effects of the Hallucinogen Psilocybin on Covert Orienting of Visual Attention in Humans

Neuropsychobiology 2002 Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Stefanie Maier et al. 69 citations

Hallucinogenic drug-induced states are considered as models for acute schizophrenic disorders (experimental psychoses). In a double-blind study with healthy volunteers we investigated the influence of the serotonergic hallucinogen psilocybin, the ecstasy-like drug 3,4-methylenedioxyethylamphetamine (MDE), the stimulant d- methamphetamine and placebo on covert orienting of spatial attention (n =...

Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers

Psychopharmacology February 18, 1999 Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Elmar Habermeyer et al. 145 citations

The aim of this study was to contribute to the characterization of the entactogen (ecstasy) substance group. The psychopathological, neuroendocrine and autonomic effects of common recreational doses of the entactogen 3,4-methylenedioxyethylamphetamine (MDE), the hallucinogen psilocybin, the stimulant d-methamphetamine and placebo were investigated in a double-blind study with healthy volunteers...

Methodological Issues of Human Experimental Research with Hallucinogens

Pharmacopsychiatry July 1, 1998 Euphrosyne Gouzoulis‐mayfrank, Frank Schneider, J. Friedrich et al. 16 citations

Human experimental research with hallucinogenic drugs is potentially able to identify linking variables between the psycho(patho)logical conditions and neurobiological alterations involved in both pharmacologically induced and naturally occurring acute psychotic states. A number of methodological aspects should be considered when planning modern experimental studies with hallucinogenic drugs....